but also some positive studies that suggest TIGIT may have a role to play in some cancers. Novartis also partners BeiGene on PD-1 inhibitor tislelizumab, a drug that is already approved in China ...

The combination of Merck & Co’s PD-1 inhibitor Keytruda with experimental TIGIT inhibitor vibostolimab has generated disappointing results in a mid-stage lung cancer trial. The open-label ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

with other TIGIT inhibitors still under development, including domvanalimab, rilvegostomig, and belrestotug. Govindan also said that not all TIGIT inhibitors are the same and that there is a ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab ... and colleagues noted that anti-CTLA-4-based dual immune checkpoint inhibitor regimens have "revolutionized the treatment paradigm ...

Instead, the company will focus on other programmes, including its TIGIT therapies ... to chemotherapy after treatment with PD-1/PD-L1 inhibitors and demonstrated that this saw an average ORR ...

Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The ...

The company's pipeline, particularly its HIF2alpha inhibitor casdatifan and TIGIT programs, has positioned it as a potential leader in the oncology space. This comprehensive analysis examines ...

The company’s pipeline, particularly its HIF2alpha inhibitor casdatifan and TIGIT programs, has positioned it as a potential leader in the oncology space. This comprehensive analysis examines Arcus ...